Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Top Cited Papers
- 8 October 2010
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 376 (9747), 1147-1154
- https://doi.org/10.1016/s0140-6736(10)61389-x
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid TumorsClinical Cancer Research, 2009
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate CancerClinical Cancer Research, 2008
- A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patientsAnnals of Oncology, 2008
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working GroupJournal of Clinical Oncology, 2008
- Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patientsCancer, 2007
- Quality of Life and Pain in Advanced Stage Prostate Cancer: Results of a Southwest Oncology Group Randomized Trial Comparing Docetaxel and Estramustine to Mitoxantrone and PrednisoneJournal of Clinical Oncology, 2006
- Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cyclesBritish Journal of Cancer, 2006
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerThe New England Journal of Medicine, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- The McGill Pain Questionnaire: Major properties and scoring methodsPain, 1975